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Abstract
Introduction: Accelerated cardiovascular (CV) disease significantly contributes to increased mortality in rheumatoid
arthritis (RA) patients, with a risk comparable to the one observed in patients with type 2 diabetes mellitus (DM).
Part of this enhanced risk in RA is attributed to traditional cardiovascular risk factors (CRFs). The aims of this study
were to determine how often traditional CRFs are identified and managed by (a) rheumatologists, compared with
primary care physicians (PCPs) in RA patients; and (b) PCPs among patients with RA, DM, and the general
population (GP).
Methods: A retrospective cohort study compared age/gender/ethnicity-matched patients from three groups: RA,
DM, and GP (without RA or DM); n = 251 patients per group. Electronic patient records were reviewed during a
continuous 12-month period between June 2007 and April 2011 to assess whether CRFs were identified and
managed.
Results: In RA patients, PCPs managed obesity, BP, and lipids significantly more often than did rheumatologists.
PCPs managed obesity, BP, and lipids significantly more often in diabetic patients than in the other two groups,
and more often in the GP than in RA patients. In patients with elevated BMI, PCPs managed weight in 68% of the
DM group, 46% of the GP, and 31% of the RA group (P < 0.0001 for all groups; P = 0.006 between RA and GP
groups).
Conclusions: Rheumatologists identify and manage CRFs less frequently than PCPs. PCPs manage CRFs less
frequently in RA patients, compared to the GP and DM. Given the increased CV risk associated with RA, physicians
need to more aggressively manage CRFs in these patients.
Introduction
In patients with rheumatoid arthritis (RA), the leading
cause of mortality is accelerated atherosclerotic cardio-
vascular disease (CVD), with standardized mortality
ratios between 1.3 and 3 [1,2]. Patients with RA have a
twofold increased risk for myocardial infarction (MI),
and a 10-year risk of CV events that is 60% higher than
that in the general population [3,4]. The increased CV
risk in RA patients is considered secondary to both dis-
ease-specific mechanisms associated with enhanced
inflammatory burden, and to traditional CV risk factors
(CRFs), such as diabetes mellitus (DM)/insulin resis-
tance, smoking, obesity, hypertension, and dyslipidemia
[5-8].
RA and DM share a similarly increased risk of CV
events [9,10]. However, although the frequency and
severity of preclinical atherosclerosis is equal in RA and
DM of similar duration, a differential impact seems to
exist when comparing traditional risk factors versus sys-
temic inflammation in both diseases. Traditional risk
factors seem to play a greater role in CVD associated
with DM, whereas systemic inflammation appears to
play a greater role in RA [11]. Preliminary guidelines
exist for CV risk prevention in RA, but these are cer-
tainly far more clearly established and validated in DM
[12,13].
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We hypothesized that traditional CRFs are not as fre-
quently managed in patients with RA, as compared with
patients with DM or with the general population (GP).
We based this assumption on several observations. First,
the awareness of the increased CV risk and primary pre-
vention guidelines differs between RA and DM, as sup-
ported by the discrepancy in the strength of CV risk-
prevention guidelines [12,13]. Second, several studies
indicate potential suboptimal identification and treat-
ment of CRFs in RA [14,15]. Third, as in DM, symp-
toms of angina and MI often go unrecognized in RA.
Patients with RA are twice as likely to develop silent
MIs and sudden cardiac death than is the general popu-
lation [16]. Finally, it has been shown that patients with
chronic illnesses have unrelated conditions that are
often undertreated [17].
This study analyzed how frequently traditional CRFs
were identified and managed by rheumatologists com-
pared with PCPs in patients with RA in a tertiary care
center. In addition, this study assessed how frequently
these traditional CRFs were identified and managed by
PCPs among patients with RA, DM, and the GP.
Materials and methods
Study design
We performed a retrospective cohort study to compare
identification and management of traditional CRFs at a
tertiary care center among age-, gender-, and ethnicity-
matched patients from three groups: RA, type 2 DM,
and GP (without RA or DM). Specifically, we deter-
mined how frequently CRFs were identified and mana-
ged by (a) rheumatologists and primary care physicians
(PCPs) in patients with RA; and (b) PCPs in patients
with RA, compared with those with DM or with the GP.
Electronic patient records were reviewed during a con-
tinuous 12-month period, at some time between June
2007 and April 2012, to assess whether CRFs were iden-
tified and managed. Identification was defined as docu-
menting the CRF at any visit. Management was defined
as documenting a plan to address the CRF.
Patient population
Patients from all three groups were required to have
established care at the University of Michigan Health
System (UMHS) for at least a 12-month period. Lists of
patients were obtained from the University of Michigan
Medical Center Information Technology (MCIT) after
IRB approval. No patient consent was required, given
that the study was a retrospective chart review. For the
RA group, adult patients were included if they had an
ICD9 diagnosis code of 714.0 (RA), had no diagnosis of
type 1 or type 2 diabetes, and had been evaluated by a
rheumatologist and a PCP in the UMHS during the
same 12-month period. Once this list was obtained, the
records were reviewed, and only those patients who ful-
filled the 1987 ACR criteria for RA, with 1 or more
years of disease duration, were included [18]. Patients
with a diagnosis of systemic lupus erythematosus, undif-
ferentiated connective tissue disease, Still’s disease, other
well-defined connective tissue diseases, polyarthritis due
to a viral illness, or an uncertain diagnosis of RA were
excluded. For the DM group, patients were included if
they had an ICD9 diagnosis code of 250.00-250.92, con-
sistent with type 2 diabetes. Once this list was obtained,
the records were reviewed, and only those who fulfilled
a diagnosis of type 2 diabetes, per the accepted criteria,
were included [19]. Patients with a diagnosis of glucose
intolerance who did not fulfill criteria for DM were
excluded. For the GP group, patients were excluded if
they had a diagnosis of RA and/or DM. Patients were
age, race, and ethnicity matched among the three groups
via random selection.
Data collection and analysis
Baseline characteristics
For the RA group, the 12-month period for review was
determined by finding the most recent visit to the Rheu-
matology Outpatient Clinic with a match of at least one
PCP visit during the preceding 12 months. For the other
two groups, this period was defined as the 12 months
preceding the most recent PCP visit. Given that all
rheumatology and primary care physician visit records
were available in the same electronic medical record sys-
tem and that all providers had access to this system, it is
considered that the rheumatologists and PCPs monitor-
ing a given RA patient were aware that the patient was
under the care of both departments in the health
system.
Demographic and clinical characteristics at baseline
were assessed and captured. These included age, race,
gender, smoking status, duration of disease, medications,
and C-reactive protein (CRP) level. Smoking status was
defined as a lifelong nonsmoker, past smoker, or current
smoker. Duration of disease was determined by how
long the symptoms leading to diagnosis had been
ongoing, or when the diagnosis was made, if sympto-
matic duration was not mentioned in the records. Nota-
ble classes of medications that patients were taking
included disease-modifying antirheumatic agents
(DMARDs), biologics, insulin, antiglycemic agents,
NSAIDs, antihypertensives, lipid-lowering agents, antic-
oagulation, and aspirin. The type and dosage for each
class of medication was recorded. For patients with RA,
the most recent CRP level was recorded, if available
within 2 years of the visit. For patients with diabetes,
the most recent hemoglobin A1c was recorded, if avail-
able within 2 years of the visit. For every patient, a per-
sonal history of hypertension (HTN), hyperlipidemia
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(HL), coronary artery disease (CAD), myocardial infarc-
tion (MI), and cerebrovascular accident (CVA) was
noted if present. A family history of CAD, MI, or CVA
was noted and recorded as positive if present in any
first-degree relative, including parents, siblings, or chil-
dren. The age at onset of a particular CV event was not
considered in the definition of a family history, as the
majority of physician notes did not include this
information.
CRF assessment
Two components composed each CRF: identification
and management. The CRF interventions included
smoking cessation, weight-management strategies, BP
control, lipid profile control, and fasting blood glucose
(FBG) management strategies.
Smoking cessation was considered as identified if a
physician assessed and recorded a patient’s smoking sta-
tus, regardless of the actual status. The issue was con-
sidered to be managed if a physician either encouraged
continued smoking abstinence for a lifelong nonsmoker
or former smoker, or if the physician provided active
smoking-cessation counseling or medical treatment for a
current smoker.
Exercise status was defined as whether or not a
patient exercised. If a patient was found to exercise, the
frequency of exercise was determined as infrequent (1
to 2 times weekly or less), moderate (3 to 4 times
weekly), or regular (5 or more times weekly). If a patient
was found to exercise, but no frequency was recorded,
then it was assumed that the patient exercised regularly.
If no mention of exercise was made, then this section
was listed as no data.
Weight was considered to be identified if a physician
noted exercise status, any recent weight changes, or
dietary habits. Simply recording a weight in the physical
examination was not sufficient to consider as weight
identification. Weight was considered to be managed if
the physician encouraged exercise initiation or continua-
tion, or dietary interventions, when warranted.
BPs were determined as an average of measurements
taken over the 12-month period, calculated separately
for systolic and diastolic values, along with the number
of measurements taken for each patient. If more than 10
measurements were taken over a given year, then only
the most recent 10 measurements were included. BP
was recorded as identified if a physician recorded a mea-
surement for any visit. BP was recorded as managed if a
physician recorded that abnormal BPs needed to be
further monitored, if BP counseling was provided, or if
antihypertensive drugs were prescribed or adjusted.
Cholesterol-profile monitoring was split into three
categories: high-density lipoprotein (HDL), low-density
lipoprotein (LDL), and triglyceride measurements. Each
category was considered to be identified if any of the
following was true: (a) a cholesterol measurement within
the prior 3 years was documented in the clinic note; (b)
a lipid profile was obtained after documentation of a
plan to monitor it; or (c) documentation alone existed
of a plan to obtain a lipid profile at the patient’s most
recent clinic visit within the 12-month study period.
Each cholesterol category was considered to be managed
if documentation of any of the following was found: (a)
the need to recheck an abnormal cholesterol level; (b)
discussion of lifestyle modifications; or (c) prescription
or adjustment of cholesterol-lowering agents.
FBG was considered to be identified and managed in a
similar manner as cholesterol. Of note, the blood glu-
cose level was recorded only if known to be a fasting
level.
Statistical analysis
Kruskal-Wallis test or Wilcoxon Rank Sum test was
used for continuous and c2 test for categoric outcomes
without accounting for matching. A subgroup analysis
was performed to assess the frequency in which patients
with abnormal values for a specific CRF had it identified
and managed. Abnormal values were considered as fol-
lows: BMI > 25, active smokers, SBP > 120, DBP > 80,
HDL < 40, triglycerides > 150, and FBG > 100. Regard-
ing LDL, an abnormal value was determined for each
patient based on the calculated Framingham LDL goal,
with a separate abnormal subgroup analysis performed
based on this value [20]. Another subgroup analysis was
performed, excluding all patients with a personal history
of CAD, MI, and/or CVA, to determine the frequency
of CRF identification and management among these
patients. All data are presented as mean ± standard
deviation or count and percentage.
Results
Baseline characteristics
In total, 359 patients were initially identified as having
RA; this number decreased to 251 patients once the
records were reviewed and noneligible patients were
excluded, as described earlier in Methods. The study
included a total of 753 patients, with 251 patients in
each group (Table 1). The mean age of patients was 49
± 10 years (81% women; 81% Caucasian). No significant
differences in disease duration were found between
patients with RA and DM, with a mean of 9.7 ± 8.7
years. Patients with DM had a significantly increased
prevalence of HTN, HL, CAD, MI, and CVA when com-
pared with the other two groups. No significant differ-
ences were noted in the prevalence of these conditions
when comparing patients with RA and the GP. BMI,
SBP, and triglycerides were significantly higher, and
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HDL and LDL were significantly lower, in patients with
DM when compared with the other two groups (Table
2). Of note, 64.5% of patients with DM were taking sta-
tins, compared with 9.2% of patients with RA and 15.1%
of the GP (P < 0.0001; Table 3). Patients with RA had a
significantly lower SBP and significantly higher HDL
compared with the GP.
Assessment of CRF identification and management in RA
patients by rheumatologists compared with PCPs
When compared with rheumatologists, PCPs identified
smoking status, weight, lipids, and FBG significantly
more frequently in RA patients (Figure 1). Furthermore,
compared with rheumatologists, PCPs managed weight,
BP, lipids, and FBG significantly more frequently in RA
Table 1 Baseline demographic characteristics of each cohort
N = 251/group Group A (RA) Group B (DM) Group C (GP) P; All three P; A versus C
Age Years (SD) 48.5 (10.0) 49.1 (9.8) 49.0 (9.3) 0.8
Gender Male 47 (19%) 47 (19%) 47 (19%) 1
Female 204 (81%) 204 (81%) 204 (81%)
Race Caucasian 203 (81%) 203 (81%) 203 (81%)
African-American 27 (11%) 27 (11%) 27 (11%)
Asian 17 (7%) 17 (7%) 17 (7%)
Other 4 (< 2%) 4 (< 2%) 4 (< 2%)
Disease duration Years (SD) 10.0 (8.4) 9.3 (9.0) N/A 0.08 N/A
Personal history HTN 71 (28%) 130 (52%) 71 (28%) < 0.0001 1
HL 55 (22%) 114 (45%) 48 (19%) < 0.0001 0.5
CAD 5 (2%) 27 (11%) 6 (2%) < 0.0001 1
MI 5 (2%) 12 (5%) 2 (1%) .01 0.4
CVA 4 (2%) 14 (6%) 4 (2%) .009 1
Family history CAD 74 (30%) 95 (38%) 62 (25%) 0.005 0.3
MI 30 (12%) 49 (20%) 28 (11%) 0.012 0.9
CVA 35 (14%) 25 (10%) 25 (10%) 0.3 0.2
CRP 0.9 N/A N/A
Hemoglobin A1c N/A 7.5 N/A
CAD, coronary artery disease; CRP, C-reactive protein; CVA, cerebrovascular accident; DM, diabetes mellitus; GP, general population; HL, hyperlipidemia; HTN,
hypertension; MI, myocardial infarction; N/A, not applicable; RA, rheumatoid arthritis.
Table 2 Baseline clinical characteristics of each cohort
N = 251/group Group A (RA) Group B (DM) Group C (GP) P, All three P, A versus C
Exercise status No data 165 (66%) 145 (58%) 154 (61%) < 0.0001 < 0.0001
Never 30 (12%) 46 (18%) 29 (12%)
Infrequently 1-2×/week 15 (6%) 11 (4%) 9 (4%)
Moderately 3-5×/week 31 (12%) 18 (7%) 15 (6%)
Regularly > 5×/week 10 (4%) 31 (12%) 43 (17%)
BMI 28.5 (7.5) 34.9 (8.9) 28.8 (7.9) < 0.0001 0.4
Smoking status Never 167 (67%) 155 (62%) 151 (60%) 0.2 0.7
Past 48 (19%) 48 (19%) 44 (18%)
Current 36 (14%) 48 (19%) 56 (22%)
SBP 121.8 (13.0) 130.5 (13.0) 125.0 (14.1) < 0.0001 0.02
DBP 73.3 (7.6) 72.9 (8.6) 73.2 (8.0) 0.6 0.8
Number BP measurements 6.5 (5.8) 5.8 (2.9) 4.3 (3.0) < 0.0001 < 0.0001
HDL 58.3 (17.1) 46.8 (12.9) 54.3 (15.9) < 0.0001 0.01
LDL 113.7 (32.4) 99.5 (37.1) 111.4 (29.1) < 0.0001 0.5
Triglycerides 116.9 (64.1) 192.8 (178.9) 130.6 (79.4) < 0.0001 0.1
Fasting glucose Mean (std) 90.3 (9.3) 165.5 (82.3) 93.6 (10.7) < 0.0001 0.003
N 206 166 175
BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; GP, general population; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; RA, rheumatoid arthritis; SBP, systolic blood pressure.
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patients. Weight was managed in 28.7% of RA patients
by PCPs, almost 5 times as frequently when compared
with rheumatologists. Similarly, LDL in RA patients was
managed by PCPs almost 9 times as frequently as rheu-
matologists (Figure 1A).
The subgroup analysis revealed that, in RA patients
with abnormal CRF values, PCPs identified smoking sta-
tus, weight, systolic BP, HDL, LDL, triglycerides, and
FBG significantly more frequently, when compared with
rheumatologists (Figure 1B). Further, in RA patients
with abnormal CRF values, smoking, weight, BP, LDL,
and triglycerides were managed significantly more fre-
quently by PCPs when compared with rheumatologists.
In RA patients with elevated LDL, 41.0% were managed
by PCPs, compared with 2.6% by rheumatologists (P <
0.0001).
An additional subgroup analysis was performed to
determine whether an elevated CRP level, defined as ≥
0.7 mg/dl, was associated with increased CRF identifica-
tion and/or management in RA patients, by rheumatolo-
gists or PCPs. Neither rheumatologists nor PCPs
identified CRFs any differently in RA patients with nor-
mal versus elevated CRP levels. However, rheumatolo-
gists managed BP and BMI significantly more frequently
in those with an elevated CRP level as compared with
those with a normal CRP level (12.2% versus 2.7%, P =
0.007 for BP, and 11.0% versus 3.3%, P = 0.04 for BMI).
PCPs managed BP significantly more frequently in RA
patients with an elevated compared with normal CRP
level (34.2% versus 15.9%; P = 0.002).
CRF identification and management by PCPs in patients
with RA, DM, and of the GP
PCPs identified weight, lipids, and FBG significantly
more frequently in patients with DM, when compared
with those with RA or with the GP. In contrast,
smoking status was identified significantly more fre-
quently in the GP when compared with the other two
groups (Table 4). In addition, PCPs identified weight,
BP, and lipids significantly more frequently in the GP
when compared with RA patients.
Weight, BP, lipids, and FBG were managed signifi-
cantly more frequently in DM patients, when compared
with the other two groups. PCPs managed weight, BP,
lipids, and FBG significantly more frequently in the GP,
as compared with patients with RA.
A subgroup analysis, evaluating patients with abnor-
mal values for each risk factor, found that PCPs identi-
fied weight, lipids, and FBG and managed weight, BP,
lipids, and FBG significantly more frequently in DM,
when compared with RA or GP patients (Table 5). In
this subset of patients, PCPs identified and managed
abnormal weight significantly more frequently in
patients of the GP when compared with patients with
RA. In patients with elevated BMI, PCPs managed
weight in 68.0% of DM patients, 45.7% of GP patients,
and 30.6% of RA patients (P <0.0001 in all groups and P
= 0.006 in GP versus RA groups; Figure 2).
An additional subgroup analysis excluding all patients
with a history of CVD, defined as CAD, MI, and/or
CVA, found that PCPs identified and managed smoking
status, weight, BP, HDL, LDL, and triglycerides signifi-
cantly more frequently in DM, when compared with RA
and with GP patients (all P values < 0.05; Figure 3A). In
addition, weight, BP, HDL, LDL, and triglycerides were
identified and managed significantly more frequently in
the GP patients, when compared with RA patients (all P
values < 0.05). When assessing patients without a his-
tory of CVD and with abnormal values for each CRF,
PCPs managed weight, BP, HDL, LDL, and triglycerides
significantly more frequently in patients with DM, when
compared with RA or the GP (all P < 0.05; Figure 3B).
Table 3 Baseline intake of medications in each cohort
N = 251/group Group A (RA) Group B (DM) Group C (GP) P, all three P, A versus C
Medications
RA MTX 126 (50%) N/A N/A – –
HCQ 92 (37%) N/A N/A – –
PDN 86 (34%) N/A N/A – –
TNF 96 (38%) N/A N/A – –
DM Insulin N/A 100 (40%) N/A – –
Metformin N/A 132 (53%) N/A – –
NSAIDs 74 (29%) 43 (17%) 51 (20%) 0.003 0.02
Anti-HTN 66 (26%) 180 (72%) 86 (34%) < 0.0001 0.052
Statin 23 (9%) 162 (65%) 38 (15%) < 0.0001 0.055
ASA 81 mg 22 (9%) 93 (37%) 33 (13%) < 0.0001 0.12
> 81 mg 5 (2%) 16 (6%) 6 (2%) 0.01 0.76
Anti-HTN, antihypertensives; ASA, aspirin; DM, diabetes mellitus; GP, general population; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N/A, not
applicable; NSAIDs, nonsteroidal antiinflammatory drugs; PDN, prednisone; RA, rheumatoid arthritis; TNF, anti-TNF agents.
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Figure 1 CRF identification and management in patients with RA. (A) CRF identification and management by rheumatologists compared
with PCPs in RA patients. Results represent the percentage of RA patients whose CRFs were identified or managed by rheumatologists,
compared with primary care physicians; the numeric value above each bar in the figure represents this percentage. (B) Suboptimal CRF
identification and management by rheumatologists compared with PCPs in RA patients. All patients included in this subgroup analysis had RA
and an abnormal value for a given risk factor. Results represent the percentage of RA patients whose abnormal CRFs were identified and/or
managed by rheumatologists compared with primary care physicians. The fraction above each bar in the graph represents the number of
patients whose abnormal CRF was identified or managed, divided by the total number of patients in the group with an abnormal CRF. BP,
blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCP, primary care physician.
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Table 4 CRF identification and management by rheumatologists in RA; PCPs in RA, DM, and the GP
Group A (RA)
Rh
Group A (RA)
PCP
Group B (DM) Group C (GP) P, Group A
(Rh versus PCP)
P, all three (PCP) P, A versus
C (PCP)
Smoking ID 52 (21%) 167 (67%) 161 (64%) 188 (75%) < 0.0001 0.02 0.0496
MA 32 (13%) 25 (10%) 28 (11%) 39 (16%) 0.4 0.1 0.08
Weight ID 67 (27%) 111 (44%) 191 (76%) 136 (54%) < 0.0001 < 0.0001 0.03
MA 15 (6%) 72 (29%) 159 (63%) 99 (39%) < 0.0001 < 0.0001 0.01
BP ID 233 (93%) 243 (97%) 250 (99.6%) 250 (99.6%) 0.07 0.04
MA 14 (6%) 53 (21%) 169 (67%) 80 (32%) < 0.0001 < 0.0001 0.008
HDL ID 13 (5%) 109 (43%) 190 (76%) 144 (57%) < 0.0001 < 0.0001 0.002
MA 5 (2%) 34 (14%) 137 (55%) 70 (28%) < 0.0001 < 0.0001 0.0001
LDL ID 14 (6%) 110 (44%) 197(79%) 146 (58%) < 0.0001 < 0.0001 0.004
MA 4 (2%) 38 (15%) 160 (64%) 78 (31%) < 0.0001 < 0.0001 < 0.0001
TG ID 14 (6%) 109 (43%) 190 (76%) 141 (56%) < 0.0001 < 0.0001 0.006
MA 5 (2%) 36 (14%) 142 (57%) 70 (28%) < 0.0001 < 0.0001 0.0003
FBG ID 3 (1%) 58 (23%) 237 (94%) 68 (27%) < 0.0001 < 0.0001 0.4
MA 0 7 (3%) 232 (92%) 19 (8%) 0.02 < 0.0001 0.03
Percentages are calculated as the number of patients with an identified or managed risk factor divided by the total number of patients within the group. BP,
blood pressure; CRF, cardiovascular risk factor; DM, diabetes mellitus; FBG, fasting blood glucose; GP, general population; HDL, high-density lipoprotein; ID,
identified; LD, low-density lipoprotein; MA, managed; PCP, primary care physician; RA, rheumatoid arthritis; Rh, rheumatologist; TG, triglyceride.
Table 5 Subgroup analysis: identification and management of abnormal CRFs
Group A (RA)
Rh
Group A (RA)
PCP
Group B (DM) Group C (GP) P, Group A
(Rh versus PCP)
P, all three
(PCP)
P, A versus
C (PCP)
Smoking Abnl (n) 36 36 48 56
ID 6 (17%) 29 (81%) 40 (83%) 49 (88%) < 0.0001 0.7 0.4
MA 5 (14%) 20 (56%) 25 (52%) 34 (61%) 0.0004 0.7 0.7
Weight Abnl (n) 160 160 222 162
ID 41 (26%) 72 (45%) 176 (79%) 92 (57%) 0.0004 < 0.0001 0.04
MA 13 (8%) 49 (31%) 151 (68%) 74 (46%) < 0.0001 < 0.0001 0.006
SBP Abnl (n) 132 132 199 150
ID 119 (90%) 131 (99%) 198 (99.9%) 149 (99%) 0.001 0.9 1
MA 12 (9%) 44 (33%) 146 (73%) 64 (43%) < 0.0001 < 0.0001 0.1
DBP Abnl (n) 45 45 45 52
ID 43 (96%) 45 45 52 0.5 1 1
MA 8 (18%) 18 (40%) 35 (78%) 30 (58%) 0.04 < 0.001 0.1
HDL Abnl (n) 26 26 75 33
ID 2 (8%) 11 (42%) 56 (75%) 22 (67%) 0.009 < 0.01 0.07
MA 1 (4%) 4 (15%) 38 (51%) 13 (39%) 0.3 < 0.0001 0.08
LDL Abnl (n) 39 39 102 33
ID 1 (3%) 23 (59%) 85 (83%) 26 (79%) < 0.0001 0.009 0.08
MA 1 (3%) 16 (41%) 76 (75%) 21 (64%) < 0.0001 0.0009 0.06
TG Abnl (n) 53 53 130 54
ID 6 (11%) 31 (59%) 110 (85%) 36 (67%) < 0.0001 < 0.0003 0.4
MA 3 (6%) 17 (32%) 86 (66%) 20 (37%) 0.0009 < 0.0001 0.7
FBG Abnl (n) 26 26 141 36
ID 0 12 (46%) 135 (96%) 16 (44%) < 0.0001 < 0.0001 1
MA 0 2 (8%) 132 (94%) 8 (22%) 0.5 < 0.0001 0.2
All patients included in this subgroup analysis had an abnormal value for a given risk factor. Percentages are calculated as the number of patients with an
identified or managed risk factor divided by the number of patients with abnormal values for the given risk factor. Abnl, abnormal; DBP, diastolic blood pressure;
DM, diabetes mellitus; FBG, fasting blood glucose; GP, general population; HDL, high-density lipoprotein; ID, identified; LDL, low-density lipoprotein; MA,
managed; RA, rheumatoid arthritis; Rh, rheumatologist; SBP, systolic blood pressure; TG, triglyceride.
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In these same patients, PCPs managed weight, LDL, and
HDL significantly more frequently in GP as compared
with RA patients (all P < 0.05).
Overall, rheumatologists identified and managed CRFs
significantly less frequently in RA patients, when compared
with PCPs. Abnormal BMI, BP, and lipid profiles were
most frequently identified and managed by PCPs in
patients with DM, compared with patients with RA. Abnor-
mal BMI was more frequently identified and managed by
PCPs in the GP, when compared with patients with RA.
Discussion
In this cohort study performed at a tertiary-care center
in the United States, we found that rheumatologists
identify and manage CRFs in RA patients significantly
less frequently than PCPs. This is in agreement with
another study that reported that RA patients are better
screened for CRFs when also followed up by a PCP
rather than only by a rheumatologist. In particular, that
study reported that RA patients who were followed up
only by a rheumatologist, underwent lipid screening
22% of the time versus 43% to 51% when PCPs were
also involved [15]. These results indicate the need for
improved collaboration between PCPs and rheumatolo-
gists to screen RA patients for primary CRF prevention.
In addition, our study found that abnormal BMI, BP,
and lipid profiles are most frequently identified and
managed by PCPs in patients with DM than in those
with RA. More surprising is that abnormal BMI is more
frequently identified and managed by PCPs in the GP
when compared with patients with RA. This indicates
that, although patients with RA have a well-established
increased CV risk, equivalent to the risk observed in
DM, traditional CRFs in RA are not adequately identi-
fied and managed, even to a degree comparable with
that of the GP [21]. This underrecognition and underas-
sessment of CV risk in RA patients is a finding further
discussed in a recently published study that involved
sending questionnaires to PCPs and asking them about
their awareness of and clinical practices regarding CV
risk and RA [22]. In that study, only 32% of PCPs iden-
tified RA as an independent risk factor for CVD, and
15% of PCPs assessed RA patients for primary preven-
tion of CV risks. In addition, they discovered that PCPs
who had received some type of education on increased
CV risk in RA more frequently assessed CV risk. How-
ever, of those PCPs, only 40% performed primary pre-
vention risk assessment. These findings highlight the
suboptimal awareness of CVD in RA among primary
care providers, and further support our results.
Perhaps if better established primary prevention guide-
lines existed regarding CRF management in RA, as pro-
posed by EULAR, more active management of these
CRFs by providers would be observed [13]. Current
models to predict the risk of CVD for the general popu-
lation, such as the general Framingham and the Rey-
nolds risk scores, underestimate CV risk in patients with
RA, according to one study [23]. Indeed, the observed
CVD risk in RA patients was twofold higher in women
and 65% higher in men, when compared with that pre-
dicted by the Framingham risk score. These results
emphasize the need for more accurate models to predict
CV risk in RA. In addition, further studies should be
pursued to determine the efficacy of the available
EULAR recommendations, to better formulate and
establish primary prevention guidelines regarding CRF
management in RA.
The baseline characteristics in our study reveal no dif-
ferences in the prevalence of some of the traditional
CRFs and previous CV events between RA patients and
the GP, in contrast to what may be expected, given the
known increased CV risk in RA and prior findings in
the published literature [6,7,24]. Also, RA patients in
our study were found to have significantly lower SBP
and significantly higher HDL when compared with the
GP. This is also in contrast with other studies that
reported lower HDL levels in RA compared with the GP
[7,25]. These findings may be because the average age of
patients in our study was 49 years, 8 years younger than
the average age of patients in studies reporting higher
prevalence of CAD, MI, and CVA, and/or lower HDL
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levels [3,25]. Furthermore, White et al. [26] found a sta-
tistically significant inverse relation between HDL and
CRP levels. RA patients in our study were found to have
relatively well-controlled disease, with overall low CRP
levels. This could potentially explain the higher-than-
expected HDL levels. Also, the mere quantification
of HDL in RA may not reveal true CV risk, as these
patients have higher prevalence of oxidized HDL, which
loses its antiinflammatory properties and may become
proatherogenic [27]. In addition, our study excluded
patients with RA coexisting with DM to reduce con-
founding factors. This may have skewed our baseline
characteristics, given that these patients with the highest
risk were excluded.
Our study found that DM patients had significantly
lower LDL levels compared with the other two groups,
which may be because a significantly higher percentage
of diabetes patients were taking a statin (P < 0.0001). As
expected, DM patients had significantly higher BMI,
SBP, and triglyceride measurements.
Limitations of our study include that rheumatologists
may have not addressed certain CRFs in RA because
they were aware that their patients were also being fol-
lowed up by a PCP. It is possible that the same rheuma-
tologist would have more actively identified and
managed these CRFs if the patient were not seen by a
PCP. Similarly, rheumatologists may not have addressed
CRFs with RA patients if these patients were first exam-
ined by a PCP. It should be kept in mind that, although
PCPs were shown to identify and manage CRFs better
in RA compared with rheumatologists, they still did not
adequately address their CRFs when compared with the
GP. Therefore, even when patients are followed up by
PCPs, rheumatologists should be vigilant about the
detection and management of CV risk in RA patients.
A second limitation of our study is that the data were
gathered retrospectively from medical charts. Hence, if
the provider identified or managed a CRF but did not
document it, the particular CRF would be considered as
not addressed for the purposes of our study. We assume
that this likely occurred equally in all three groups, so
the relative discrepancies seen would still be present.
Our study has several strengths, including that we per-
formed an extensive chart review of a large cohort of
patients (n = 753). Although a prior study assessed the
management of individual CRFs, to our knowledge, no
other studies performed such a thorough assessment of
the management of multiple CRFs in RA [15]. In addi-
tion, no other studies have simultaneously assessed CRF
management in patients with RA when compared with
those with DM, a more-established CAD risk equivalent.
Finally, our study accounted for the overall CVD his-
tory and for individual risk-factor abnormalities in the
subgroup analyses. We found that, at baseline, there was
about a fivefold increase in the prevalence of a history
of CVD in DM as compared with RA or GP patients.
Therefore, the higher frequency of CRF identification
and management found in DM patients could poten-
tially have been due to the increased prevalence of CVD
in this group. However, when excluding patients with a
history of CVD, we found that PCPs still identified and
managed certain CRFs most frequently in DM, followed
by GP, and then RA patients. These findings persisted
when looking at patients without CVD and with abnor-
mal CRF values.
Conclusions
In summary, we found that despite rheumatologists’
awareness of increased CV risk in RA patients, they are
significantly less likely to identify and manage CRFs
when compared with PCPs. In addition, the manage-
ment of CRFs by general practitioners in RA patients is
suboptimal, when compared with strategies implemen-
ted in the GP and DM patients. We hypothesize that
health care providers spend more time focusing on
rheumatologic issues rather than seemingly less-pressing
primary prevention issues. However, given the well-
established increased CV risk associated with RA, both
rheumatologists and PCPs should collaborate and more
aggressively identify and manage CRFs in patients with
RA to minimize their deleterious effects on morbidity
and mortality.
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